Association between the β-blocker use and patients with sepsis: a cohort study

Front Med (Lausanne). 2023 Oct 26:10:1272871. doi: 10.3389/fmed.2023.1272871. eCollection 2023.

Abstract

Objective: This study aimed to assess whether β-blockers are associated with mortality in patients with sepsis.

Method: We conducted a retrospective cohort study of patients with sepsis using the Medical Information Market for Intensive Care (MIMIC)-IV and the emergency intensive care unit (eICU) databases. The primary outcome was the in-hospital mortality rate. The propensity score matching (PSM) method was adopted to reduce confounder bias. Subgroup and sensitivity analyses were performed to test the stability of the conclusions.

Results: We included a total of 61,751 patients with sepsis, with an overall in-hospital mortality rate of 15.3% in MIMIC-IV and 13.6% in eICU. The inverse probability-weighting model showed that in-hospital mortality was significantly lower in the β-blockers group than in the non-β-blockers group [HR = 0.71, 95% CI: 0.66-0.75, p < 0.001 in MIMIC-IV, and HR = 0.48, 95% CI: 0.45-0.52, p < 0.001 in eICU]. In subgroups grouped according to sex, age, heart rate, APSIII, septic shock, and admission years, the results did not change.

Conclusion: β-blocker use is associated with lower in-hospital mortality in patients with sepsis, further randomized trials are required to confirm this association.

Keywords: critically ill patients; in-hospital mortality; sepsis; septic shock; β-blocker.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors gratefully acknowledge financial support by Guangzhou Municipal Science and Technology Project (202102010068) and The Natural Science Foundation of Guangdong Province (2022A1515010397 and 2023A1515011988).